Promoting activity of (α4)3(β2)2 nicotinic cholinergic receptors reduces ethanol consumption

Abstract

There is increasing interest in developing drugs that act at α4β2 nicotinic acetylcholine receptors (nAChRs) to treat alcohol use disorder. The smoking cessation agent varenicline, a partial agonist of α4β2 nAChRs, reduces alcohol intake, but its use can be limited by side effects at high therapeutic doses. There are two stoichiometric forms of α4β2 nAChRs, (α4)3(β2)2 and (α4)2(β2)3. Here we investigated the hypothesis that NS9283, a positive allosteric modulator selective for the (α4)3(β2)2 form, reduces ethanol consumption. NS9283 increased the potency of varenicline to activate and desensitize (α4)3(β2)2 nAChRs in vitro without affecting other known targets of varenicline. In male and female C57BL/6J mice, NS9283 (10 mg/kg) reduced ethanol intake in a two-bottle choice, intermittent drinking procedure without affecting saccharin intake, ethanol-induced incoordination or ethanol-induced loss of the righting reflex. Subthreshold doses of NS9283 (2.5 mg/kg) plus varenicline (0.1 mg/kg) synergistically reduced ethanol intake in both sexes. Finally, despite having no aversive valence of its own, NS9283 enhanced ethanol-conditioned place aversion. We conclude that compounds targeting the (α4)3(β2)2 subtype of nAChRs can reduce alcohol consumption, and when administered in combination with varenicline, may allow use of lower varenicline doses to decrease varenicline side effects.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. 1.

    Litten RZ, Egli M, Heilig M, Cui C, Fertig JB, Ryan ML. et al. Medications development to treat alcohol dependence: a vision for the next decade. Addict Biol. 2012;17:513–27.

  2. 2.

    Litten RZ, Wilford BB, Falk DE, Ryan ML, Fertig JB. Potential medications for the treatment of alcohol use disorder: an evaluation of clinical efficacy and safety. Subst Abus. 2016;37:286–98.

  3. 3.

    McKee SA, Harrison EL, O’Malley SS, Krishnan-Sarin S, Shi J, Tetrault JM. et al. Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiatry. 2009;66:185–90.

  4. 4.

    O’Malley SS, Zweben A, Fucito LM, Wu R, Piepmeier ME, Ockert DM, et al. Effect of varenicline combined with medical management on alcohol use disorder with comorbid cigarette smoking: a randomized clinical trial. JAMA Psychiatry. 2018;75:129–38.

  5. 5.

    Verplaetse TL, Pittman BP, Shi JM, Tetrault JM, Coppola S, McKee SA. Effect of lowering the dose of varenicline on alcohol self-administration in drinkers with alcohol use disorders. J Addict Med. 2016;10:166–73.

  6. 6.

    Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE. et al. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med. 2013;7:277–86.

  7. 7.

    Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D. et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387:2507–20.

  8. 8.

    Campling BG, Kuryatov A, Lindstrom J. Acute activation, desensitization and smoldering activation of human acetylcholine receptors. PLoS ONE. 2013;8:e79653

  9. 9.

    Lummis SC, Thompson AJ, Bencherif M, Lester HA. Varenicline is a potent agonist of the human 5-hydroxytryptamine3 receptor. J Pharm Exp Ther. 2011;339:125–31.

  10. 10.

    Wang J, Lindstrom J. Orthosteric and allosteric potentiation of heteromeric neuronal nicotinic acetylcholine receptors. Br J Pharmacol. 2018;175:1805–21.

  11. 11.

    Nelson ME, Kuryatov A, Choi CH, Zhou Y, Lindstrom J. Alternate stoichiometries of alpha4beta2 nicotinic acetylcholine receptors. Mol Pharmacol. 2003;63:332–41.

  12. 12.

    Tapia L, Kuryatov A, Lindstrom J. Ca2+ permeability of the (alpha4)3(beta2)2 stoichiometry greatly exceeds that of (alpha4)2(beta2)3 human acetylcholine receptors. Mol Pharmacol. 2007;71:769–76.

  13. 13.

    Hendrickson LM, Zhao-Shea R, Pang X, Gardner PD, Tapper AR. Activation ofalpha4* nAChRs is necessary and sufficient for varenicline-induced reduction of alcohol consumption. J Neurosci. 2010;30:10169–76.

  14. 14.

    Hendrickson LM, Zhao-Shea R, Tapper AR. Modulation of ethanol drinking-in-the-dark by mecamylamine and nicotinic acetylcholine receptor agonists in C57BL/6J mice. Psychopharmacology. 2009;204:563–72.

  15. 15.

    Slater CA, Jackson A, Muldoon PP, Dawson A, O’Brien M, Soll LG. et al. Nicotine enhances the hypnotic and hypothermic effects of alcohol in the mouse. Alcohol Clin Exp Res. 2016;40:62–72.

  16. 16.

    Harpsoe K, Ahring PK, Christensen JK, Jensen ML, Peters D, Balle T. Unraveling the high- and low-sensitivity agonist responses of nicotinic acetylcholine receptors. J Neurosci. 2011;31:10759–66.

  17. 17.

    Wang J, Kuryatov A, Sriram A, Jin Z, Kamenecka TM, Kenny PJ, et al. An accessory agonist binding site promotes activation of alpha4beta2* nicotinic acetylcholine receptors. J Biol Chem. 2015;290:13907–18.

  18. 18.

    Timmermann DB, Sandager-Nielsen K, Dyhring T, Smith M, Jacobsen AM, Nielsen EO, et al. Augmentation of cognitive function by NS9283, a stoichiometry-dependent positive allosteric modulator of alpha2- and alpha4-containing nicotinic acetylcholine receptors. Br J Pharmacol. 2012;167:164–82.

  19. 19.

    Jin Z, Khan P, Shin Y, Wang J, Lin L, Cameron MD, et al. Synthesis and activity of substituted heteroaromatics as positive allosteric modulators for alpha4beta2alpha5 nicotinic acetylcholine receptors. Bioorg Med Chem Lett. 2014;24:674–78.

  20. 20.

    Wang J, Kuryatov A, Jin Z, Norleans J, Kamenecka TM, Kenny PJ, et al. A novel alpha2/alpha4 subtype-selective positive allosteric modulator of nicotinic acetylcholine receptors acting from the C-tail of an alpha subunit. J Biol Chem. 2015;290:28834–46.

  21. 21.

    Kuryatov A, Mukherjee J, Lindstrom J. Chemical chaperones exceed the chaperone effects of RIC-3 in promoting assembly of functional alpha7 AChRs. PLoS ONE. 2013;8:e62246.

  22. 22.

    Hwa LS, Chu A, Levinson SA, Kayyali TM, DeBold JF, Miczek KA. Persistent escalation of alcohol drinking in C57BL/6J mice with intermittent access to 20% ethanol. Alcohol Clin Exp Res. 2011;35:1938–47.

  23. 23.

    Chen J, Rinaldo L, Lim SJ, Young H, Messing RO, Choi DS. The type 1 equilibrative nucleoside transporter regulates anxiety-like behavior in mice. Genes Brain Behav. 2007;6:776–83.

  24. 24.

    Cunningham CL, Gremel CM, Groblewski PA. Drug-induced conditioned place preference and aversion in mice. Nat Protoc. 2006;1:1662–70.

  25. 25.

    Newton PM, Messing RO. Increased sensitivity to the aversive effects of ethanol in PKCepsilon null mice revealed by place conditioning. Behav Neurosci. 2007;121:439–42.

  26. 26.

    Zapata A, Gonzales RA, Shippenberg TS. Repeated ethanol intoxication induces behavioral sensitization in the absence of a sensitized accumbens dopamine response in C57BL/6J and DBA/2J mice. Neuropsychopharmacology. 2006;31:396–405.

  27. 27.

    Obach RS, Reed-Hagen AE, Krueger SS, Obach BJ, O’Connell TN, Zandi KS, et al. Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos. 2006;34:121–30.

  28. 28.

    Kamens HM, Andersen J, Picciotto MR. Modulation of ethanol consumption by genetic and pharmacological manipulation of nicotinic acetylcholine receptors in mice. Psychopharmacology. 2010;208:613–26.

  29. 29.

    Kamens HM, Andersen J, Picciotto MR. The nicotinic acetylcholine receptor partial agonist varenicline increases the ataxic and sedative-hypnotic effects of acute ethanol administration in C57BL/6J mice. Alcohol Clin Exp Res. 2010;34:2053–60.

  30. 30.

    Kang S, Li J, Zuo W, Fu R, Gregor D, Krnjevic K, et al. Ethanol withdrawal drives anxiety-related behaviors by reducing M-type potassium channel activity in the Lateral Habenula. Neuropsychopharmacology. 2017;42:1813–24.

  31. 31.

    Cunningham CL, Niehus DR, Malott DH, Prather LK. Genetic differences in the rewarding and activating effects of morphine and ethanol. Psychopharmacology. 1992;107:385–93.

  32. 32.

    Steensland P, Simms JA, Holgate J, Richards JK, Bartlett SE. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci USA. 2007;104:12518–23.

  33. 33.

    Sotomayor-Zarate R, Gysling K, Busto UE, Cassels BK, Tampier L, Quintanilla ME. Varenicline and cytisine: two nicotinic acetylcholine receptor ligands reduce ethanol intake in University of Chile bibulous rats. Psychopharmacology. 2013;227:287–98.

  34. 34.

    Dawson A, Miles MF, Damaj MI. The beta2 nicotinic acetylcholine receptor subunit differentially influences ethanol behavioral effects in the mouse. Alcohol. 2013;47:85–94.

  35. 35.

    Liu L, Hendrickson LM, Guildford MJ, Zhao-Shea R, Gardner PD, Tapper AR. Nicotinic acetylcholine receptors containing the alpha4 subunit modulate alcohol reward. Biol Psychiatry. 2013;73:738–46.

  36. 36.

    Verplaetse TL, Pittman BP, Shi JM, Tetrault JM, Coppola S, McKee SA. Effect of varenicline combined with high-dose alcohol on craving, subjective intoxication, perceptual motor response, and executive cognitive function in adults with alcohol use disorders: preliminary findings. Alcohol Clin Exp Res. 2016;40:1567–76.

  37. 37.

    Lee CH, Zhu C, Malysz J, Campbell T, Shaughnessy T, Honore P, et al. alpha4beta2 neuronal nicotinic receptor positive allosteric modulation: an approach for improving the therapeutic index of alpha4beta2 nAChR agonists in pain. Biochem Pharmacol. 2011;82:959–66.

  38. 38.

    Pocivavsek A, Baratta AM, Mong JA, Viechweg SS. Acute kynurenine challenge disrupts sleep-wake architecture and impairs contextual memory in adult rats. Sleep. 2017;40:zsx141.

  39. 39.

    Ni KM, Hou XJ, Yang CH, Dong P, Li Y, Zhang Y, et al. Selectively driving cholinergic fibers optically in the thalamic reticular nucleus promotes sleep. Elife. 2016;5:e10382.

  40. 40.

    Shytle RD, Penny E, Silver AA, Goldman J, Sanberg PR. Mecamylamine (Inversine): an old antihypertensive with new research directions. J Hum Hypertens. 2002;16:453–57.

  41. 41.

    Wang J, Kuryatov A, Lindstrom J. Expression of clonedalpha6* nicotinic acetylcholine receptors. Neuropharmacology. 2015;96(Pt B):194–204.

  42. 42.

    Kamens HM, Silva C, McCarthy R, Cox RJ, Ehringer MA. No evidence of a role of the beta4 subunit of the nicotinic acetylcholine receptor in alcohol-related behaviors. BMC Res Notes. 2017;10:151.

  43. 43.

    Patkar OL, Belmer A, Tarren JR, Holgate JY, Bartlett SE. The effect of varenicline on binge-like ethanol consumption in mice is beta4 nicotinic acetylcholine receptor-independent. Neurosci Lett. 2016;633:235–39.

Download references

Acknowledgements

The authors thank Dr. Rajani Maiya for advice on experiments, Dr. Jody Mayfield for editing the manuscript, and Kristina Tipton for technical assistance.

Author information

Correspondence to Jingyi Wang or Robert O. Messing.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Table and Figures

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark